Literature DB >> 6642757

Increased antibody responses to Herpes virus papio (HVP) antigens in pre-lymphomatous baboons (Papio hamadryas) of the Sukhumi high lymphoma stock.

A F Voevodin, L A Yakovleva, B A Lapin, T I Ponomarjeva.   

Abstract

Antibody responses to Herpes virus papio (HVP) antigens were studied in 21 pre-lymphoma baboons (which subsequently died of malignant lymphoma), 21 paired controls, i.e. age-, sex- and population-matched healthy baboons, and 185 randomly selected healthy baboons of the same population. The sera were all collected at the same time and were tested blind in the fixed-cell indirect immunofluorescence test against HVP viral capsid antigen (VCA)-positive, early antigen (EA)-positive cell targets before and after absorption with HVP. Eleven of the pre-lymphoma sera were anti-EA-positive whereas none of the paired controls contained anti-EA. Anti-VCA titers of pre-lymphoma sera were higher than those of paired controls in thirteen cases. Only in four cases were anti-VCA titers of pre-lymphoma sera lower than those of paired controls. Qualitatively, the same results were obtained when anti-VCA and anti-EA titers of pre-lymphoma sera were compared with respective mean population values. The differences between pre-lymphoma group and control groups, especially in the case of anti-EA, were statistically highly significant. Thus, elevated anti-HVP titers in healthy baboons of the Sukhumi lymphoma-prone stock can be considered as a marker of high risk for development of malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6642757     DOI: 10.1002/ijc.2910320519

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  1 in total

1.  Genetics of primate lymphomas in a baboon (Papio hamadryas) colony of Sukhumi, USSR.

Authors:  M H Crawford; E J Devor; D H O'Rourke; L A Yakovleva; A F Voevodin; B A Lapin
Journal:  Genetica       Date:  1987-08-31       Impact factor: 1.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.